Should the medication guide be dispensed with each dispensing of QSYMIA (phentermine and topiramate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Medication Guide Dispensing Requirement for QSYMIA

Yes, the medication guide must be dispensed with each dispensing of QSYMIA (phentermine and topiramate extended-release). This is an FDA requirement clearly stated on the drug label. 1

FDA Labeling Requirement

The principal display panel on QSYMIA bottles explicitly states: "DISPENSE WITH MEDICATION GUIDE" 1. This is a mandatory FDA requirement, not an optional recommendation.

Rationale for This Requirement

QSYMIA carries several serious safety concerns that necessitate patient education with every dispensing:

Critical Safety Information Requiring Ongoing Patient Awareness

  • Teratogenicity risk - Topiramate component causes birth defects, requiring monthly pregnancy testing at home after initial healthcare professional verification 2
  • Cardiovascular effects - Can cause increased heart rate and blood pressure requiring monitoring 2
  • Psychiatric and cognitive adverse effects - Including depression, suicidal ideation, concentration/memory impairment, and anxiety 2
  • Metabolic acidosis - Requires electrolyte and creatinine monitoring before and during treatment 2
  • Acute angle-closure glaucoma - Can cause acute myopia and ocular pain 2

Additional Safety Considerations

  • Contraindications with MAOIs - Requires at least 14 days between discontinuation 2
  • Kidney stone formation risk - Acute nephrolithiasis can occur 2
  • Discontinuation protocol - The 15mg/92mg dose should not be stopped abruptly and requires tapering over at least 1 week 2
  • Drug interactions - Altered metabolism of estrogen and progestins can cause menstrual spotting in women taking birth control pills 2

Clinical Practice Implications

  • Pharmacists must provide the medication guide with every prescription fill, regardless of whether the patient is a new or continuing user 1
  • The medication guide serves as ongoing reinforcement of critical safety information, particularly important given the cognitive impairment that can occur with this medication 2
  • Patients need repeated reminders about monthly home pregnancy testing requirements and the absolute contraindication in pregnancy 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.